(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2011 (14.04.2011)

PCT

(10) International Publication Number
WO 2011/044307 A1

(51) International Patent Classification:
*C07D 271/06* (2006.01) *A61P 37/00* (2006.01)
*A61K 31/506* (2006.01) *C07D 413/14* (2006.01)
*A61P 5/00* (2006.01)

(21) International Application Number:
PCT/US2010/051727

(22) International Filing Date:
7 October 2010 (07.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/249,693 8 October 2009 (08.10.2009) US
1056094 26 July 2010 (26.07.2010) FR

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **VANDEUSEN, Christopher L.** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **WEIBERTH, Franz J.** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **GILL, Harpal S.** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **LEE, George** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **HILLEGASS, Andrea** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **KURYS, Barbara, E.** et al.; Sanofi-aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, NJ 08807 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:


— *of inventorship (Rule 4.17(iv))*

**Published**:

— *with international search report (Art. 21(3))*

WO 2011/044307 A1

(54) Title: PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS




(I)

(57) Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).